These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 7075648)

  • 1. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
    Danhof M; van Zuilen A; Boeijinga JK; Breimer DD
    Eur J Clin Pharmacol; 1982; 21(5):433-41. PubMed ID: 7075648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
    Eichelbaum M; Ochs HR; Roberts G; Somogyi A
    Arzneimittelforschung; 1982; 32(5):575-8. PubMed ID: 7201837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
    Rivière JH; Back DJ; Breckenridge AM; Howells RE
    Br J Clin Pharmacol; 1985 Nov; 20(5):469-74. PubMed ID: 3878153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.
    Danhof M; de Groot-van der Vis E; Breimer DD
    Pharmacology; 1979; 18(4):210-23. PubMed ID: 461498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of age and sex on metabolism and urinary excretion of antipyrine.
    Jorquera F; Almar M; Pozuelo M; Sansegundo D; González-Sastre M; González-Gallego J
    J Gerontol A Biol Sci Med Sci; 1998 Jan; 53(1):M14-9. PubMed ID: 9467428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.
    Teunissen MW; Kleinbloesem CH; de Leede LG; Breimer DD
    Eur J Clin Pharmacol; 1985; 28(6):681-4. PubMed ID: 4065192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
    Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ
    Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of enzyme induction on antipyrine metabolite formation.
    Danhof M; Verbeek RM; van Boxtel CJ; Boeijinga JK; Breimer DD
    Br J Clin Pharmacol; 1982 Mar; 13(3):379-86. PubMed ID: 7059438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.
    Buchanan N; Davis M; Danhof M; Breimer DD
    Br J Clin Pharmacol; 1980 Oct; 10(4):363-8. PubMed ID: 7448107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.
    Danhof M; Krom DP; Breimer DD
    Xenobiotica; 1979 Nov; 9(11):695-702. PubMed ID: 119355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine.
    Yang BB; Hounslow NJ; Sedman AJ; Forgue ST
    J Clin Pharmacol; 1996 Apr; 36(4):356-60. PubMed ID: 8728350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in metabolism and urinary excretion of antipyrine induced by aerobic conditioning.
    Villa JG; Bayon JE; González-Gallego J
    J Sports Med Phys Fitness; 1999 Sep; 39(3):197-201. PubMed ID: 10573660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.
    Posner J; Danhof M; Teunissen MW; Breimer DD; Whiteman PD
    Br J Clin Pharmacol; 1987 Jul; 24(1):51-5. PubMed ID: 3620285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of antipyrine from saliva as a measure of metabolism in man.
    Welch RM; DeAngelis RL; Wingfield M; Farmer TW
    Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of intravenous pretreatment with small liposomes on the pharmacokinetics and metabolism of antipyrine in rabbits.
    Badiola N; Al-Angary AN; Halbert GW
    J Pharm Pharmacol; 1992 Apr; 44(4):366-8. PubMed ID: 1355554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipyrine metabolite formation and excretion in patients with chronic renal failure.
    Teunissen MW; Kampf D; Roots I; Vermeulen NP; Breimer DD
    Eur J Clin Pharmacol; 1985; 28(5):589-95. PubMed ID: 4043202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chloroquine and primaquine on antipyrine metabolism.
    Back DJ; Purba HS; Park BK; Ward SA; Orme ML
    Br J Clin Pharmacol; 1983 Nov; 16(5):497-502. PubMed ID: 6639836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of antipyrine in epileptic patients.
    Rimmer EM; Routledge PA; Tsanaclis LM; Richens A
    Br J Clin Pharmacol; 1986 May; 21(5):511-4. PubMed ID: 3718808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.